147 related articles for article (PubMed ID: 32382572)
1. Determinants of Risk Factors for Renal Impairment among HIV-Infected Patients Treated with Tenofovir Disoproxil Fumarate-Based Antiretroviral Regimen in Southern Vietnam.
Hoang CQ; Nguyen HD; Vu HQ; Nguyen KT; Hoang LT; Ly H; Tat TD; Phan LT
Biomed Res Int; 2020; 2020():7650104. PubMed ID: 32382572
[TBL] [Abstract][Full Text] [Related]
2. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
Yilma D; Abdissa A; Kæstel P; Tesfaye M; Olsen MF; Girma T; Ritz C; Friis H; Andersen ÅB; Kirk O
BMC Infect Dis; 2020 Aug; 20(1):582. PubMed ID: 32762646
[TBL] [Abstract][Full Text] [Related]
3. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
[TBL] [Abstract][Full Text] [Related]
4. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tenofovor Diproxil Fumarate on Renal Function and Urinalysis Abnormalities in HIV-Infected Cameroonian Adults.
Fritzsche C; Rudolph J; Huenten-Kirsch B; Hemmer CJ; Tekoh R; Kuwoh PB; Glass A; Reisinger EC
Am J Trop Med Hyg; 2017 Nov; 97(5):1445-1450. PubMed ID: 29140230
[TBL] [Abstract][Full Text] [Related]
6. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.
Casado JL; Bañón S; Santiuste C; Serna J; Guzman P; Tenorio M; Liaño F; del Rey JM
AIDS; 2016 Jan; 30(2):231-9. PubMed ID: 26684820
[TBL] [Abstract][Full Text] [Related]
8. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
9. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
Tanuma J; Jiamsakul A; Makane A; Avihingsanon A; Ng OT; Kiertiburanakul S; Chaiwarith R; Kumarasamy N; Nguyen KV; Pham TT; Lee MP; Ditangco R; Merati TP; Choi JY; Wong WW; Kamarulzaman A; Yunihastuti E; Sim BL; Ratanasuwan W; Kantipong P; Zhang F; Mustafa M; Saphonn V; Pujari S; Sohn AH;
PLoS One; 2016; 11(8):e0161562. PubMed ID: 27560968
[TBL] [Abstract][Full Text] [Related]
10. Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.
Casado JL; Del Rey JM; Bañón S; Santiuste C; Rodriguez M; Moreno A; Perez-Elías MJ; Liaño F; Moreno S
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):416-22. PubMed ID: 26962850
[TBL] [Abstract][Full Text] [Related]
11. Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.
Huang YS; Chan CK; Tsai MS; Lee KY; Lin SW; Chang SY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2017 Oct; 50(5):595-603. PubMed ID: 26514942
[TBL] [Abstract][Full Text] [Related]
12. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T
BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472
[TBL] [Abstract][Full Text] [Related]
13. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
Decloedt EH; Lesosky M; Maartens G; Joska JA
AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
Quesada PR; Esteban LL; García JR; Sánchez RV; García TM; Alonso-Vega GG; Ferrández JS
Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
Lee JE; Lee S; Song SH; Kwak IS; Lee SH
Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
[TBL] [Abstract][Full Text] [Related]
16. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
Gallant JE; Winston JA; DeJesus E; Pozniak AL; Chen SS; Cheng AK; Enejosa JV
AIDS; 2008 Oct; 22(16):2155-63. PubMed ID: 18832879
[TBL] [Abstract][Full Text] [Related]
17. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
[TBL] [Abstract][Full Text] [Related]
18. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.
Pradat P; Le Pogam MA; Okon JB; Trolliet P; Miailhes P; Brochier C; Maynard M; Bailly F; Zoulim F; Cotte L
J Viral Hepat; 2013 Sep; 20(9):650-7. PubMed ID: 23910650
[TBL] [Abstract][Full Text] [Related]
19. Lipid profile and renal safety of tenofovir disoproxil fumarate-based anti-retroviral therapy in HIV-infected Chinese patients.
Yang J; Chen J; Ji Y; Tang Q; Zhang R; Liu L; Shen Y; Xun J; Song W; Tang Y; Wang Z; Qi T; Lu H
Int J Infect Dis; 2019 Jun; 83():64-71. PubMed ID: 30951879
[TBL] [Abstract][Full Text] [Related]
20. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B; Ngwira B; Sagno JB; Evans R
Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
